Eplerenone
- Generic Name
- Eplerenone
- Brand Names
- Inspra
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30O6
- CAS Number
- 107724-20-9
- Unique Ingredient Identifier
- 6995V82D0B
- Background
Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.
- Indication
For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.
- Associated Conditions
- Hypertension, LVEF <40% Congestive heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class II)
- Associated Therapies
- -
Effect of Eplerenone on Postprandial Inflammatory Response in Healthy Adults
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT01786551
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2017-01-05
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 44
- Registration Number
- NCT01708798
- Locations
- 🇨🇦
British Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada
Eplerenone in Hemodialysis Trial
- Conditions
- End Stage Renal DiseaseHemodialysis
- Interventions
- Drug: PlaceboDrug: eplerenone
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 158
- Registration Number
- NCT01650012
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
🇨🇦St. Joseph's Healthcare, Hamilton, Ontario, Canada
Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes
- Conditions
- Glucose IntoleranceHeart FailureType 2 Diabetes
- Interventions
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Montreal Heart Institute
- Target Recruit Count
- 62
- Registration Number
- NCT01586442
- Locations
- 🇨🇦
Montreal Heart Institute, Montreal, Quebec, Canada
Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Drug: placeboDrug: eplerenone
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Subha Raman
- Target Recruit Count
- 42
- Registration Number
- NCT01521546
- Locations
- 🇺🇸
Mattel Children's Hospital and David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸The Ohio State University Medical Center, Columbus, Ohio, United States
A Study of LY2623091 in Male and Females With Chronic Kidney Disease
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT01427972
- Locations
- 🇿🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pretoria, South Africa
Hypoglycemia and the Mineralocorticoid Receptor
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT01394627
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT01373086
- Locations
- 🇺🇸
Comprehensive Phase I, Fort Myers, Florida, United States
🇺🇸Clinical Research Atlanta, Stockbridge, Georgia, United States
🇺🇸Internal Medicine Physicians, Omaha, Nebraska, United States
Effect of Eplerenone on Endothelial Function in Metabolic Syndrome
- First Posted Date
- 2011-03-21
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 42
- Registration Number
- NCT01319344
- Locations
- 🇩🇪
Clinical Research Unit, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Nürnberg, Germany
🇩🇪Clinical Research Unit, Department of Nephrology and Hypertension, University of Erlangen-Nurnberg, Erlangen, Germany
Effect of Eplerenone in Elderly Hypertensive Early Stage Chronic Kidney Disease (CKD) Patients
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2012-07-06
- Lead Sponsor
- Jichi Medical University
- Registration Number
- NCT01302236
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.